Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Size Report, 2023-2032
The Europe pharmaceutical contract sales outsourcing (CSO) market size was estimated at USD 2.36 billion in 2022 and is expected to hit around USD 4.95 billion by 2032, poised to reach at a notable CAGR of 7.7% during the forecast period 2023 to 2032.
Key Takeaways:
Report Scope of the Europe Pharmaceutical Contract Sales Outsourcing Market
| Report Attribute | Details |
| Market Size in 2023 | USD 2.54 Billion |
| Market Size by 2032 | USD 4.95 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 7.7% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Service, Therapeutic Area |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Ashfield (UDG Healthcare plc), Syneos Health, IQVIA, Inc., GTS Solution, EVERSANA, MaBiCo, Pharmaforce Ireland, Sales Focus, Inc., Amplity Health, PharmaLex GmbH, Star OUTiCO, and NiSiPharm GmbH. |
Under contract with pharmaceutical or biotech businesses, a contract sales organization (CSO) offers various services and solutions pertaining to pharmaceutical marketing and sales activities.
Deployment of CSOs is a crucial strategic choice in the dynamic pharmaceutical sector. Medical sales outsourcing is critical for the path to commercialization. It offers qualified teams to design and manage specialized projects when the project requires commercial solutions, such as marketing, sales promotion activities, or training.
Sales representatives provide drug information and sales messaging to healthcare professionals through in-person and remote channels. CSO offers complete medical affairs solutions for non-commercial needs, including contract medical science liaisons and medical affairs consulting (MSL).
Increase in R&D and other operating costs in the pharmaceutical industry are inducing medium and large pharmaceutical companies to outsource their sales operations, as it offers cost controls, better results, and flexibility in terms of operations. This is expected to drive the pharmaceutical contract sales outsourcing (CSO) market in Europe during the forecast period.
Increase in presence of prominent players in the region, high investment in research & development for vaccines & biologics, and a surge in the number of pharmaceutical companies are other factors that are likely to drive the market in Europe.
Digitalization of Services Provided by CSOs Drives Pharmaceutical Contract Sales Outsourcing (CSO) Market
Improved and advanced services provided by the CSOs, such as in the field of non-personal promotions, are expected to drive the pharmaceutical contract sales outsourcing market share in Europe during the forecast period.
Large as well as small pharmaceutical companies are looking for drugs to cost-effectively and rapidly enter their pipelines, and CSOs play an important role in this. Rise in virtual detailing in outsourcing services is increasing dependence on CSO services.
A surge in the usage of tele-detailing drives the non-personal promotion of outsourcing. All these advanced functions including salesforce and customer support are well-established in a CSO, which can help the pharmaceutical brand to get market recognition faster.
Cost Control by Emerging Pharmaceutical Companies to Propel Market
Emerging specialty pharma firms have been looking for agreements with established pharmaceutical giants for several years in order to launch their brands.
Large pharmaceutical corporations are eager to collaborate because they need medications that can join their pipelines promptly and economically. Deals exist, ranging from selling commercialization rights entirely to licensing products. Working with a CSO enables young pharmaceutical firms to incorporate flexibility into their sales approach from the start.
Emerging businesses can quickly assemble an agile, scalable, and responsive team to meet customer demands with the help of an experienced CSO partner, thus ensuring that key market segments are serviced by the appropriate sales personnel and scaling up or down as the market demands with no negative effects on internal operations.
Increase in Research & Development Costs Boosts Demand for Personal Promotion Services
In terms of service, the pharmaceutical contract sales outsourcing (CSO) market in Europe has been classified into personal promotion, non-personal promotion, and others.
The personal promotion segment has been split into promotional sales team, key account management, and vacancy management. The non-personal promotion segment has been segregated into tele-detailing, interactive e-detailing, customer service, medical science liaisons, patient engagement services, and others.
The personal promotion segment is projected to boost the Europe pharmaceutical contract sales outsourcing market size from 2023 to 2032. Significant increase in research & development costs, technological advancements, and product innovations in biologics have prompted several pharmaceutical companies to outsource sales services to CSOs. This propels the personal promotion services segment.
Rise in Prevalence of Cancer to Augment Incremental Opportunities in Oncology
Based on therapeutic area, the pharmaceutical contract sales outsourcing (CSO) market in Europe has been divided into cardiovascular disorders, oncology, metabolic disorders, neurology, orthopedic diseases, infectious diseases, and others.
The oncology segment held a major market share in 2022. The segment is likely to expand at a higher CAGR during the forecast period. Increase in the patient population with different types of cancer is expected to drive the segment during the forecast period.
Key Developments
Some of the prominent players in the Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Europe Pharmaceutical Contract Sales Outsourcing (CSO) market.
By Service
By Therapeutic Area
By Region
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers